<DOC>
	<DOCNO>NCT00822757</DOCNO>
	<brief_summary>This study perform evaluate single 60 Mcg dose lyophilize formulation Merck Staphylococcus aureus vaccine ( V710 ) healthy subject . This study intend provide necessary safety immunogenicity data lyophilize formulation V710 prior subsequent evaluation patient risk develop serious S. aureus infection .</brief_summary>
	<brief_title>Safety Immunogenicity Study V710 Lyophilized Formulation ( V710-004 )</brief_title>
	<detailed_description />
	<criteria>18 80 year age Good physical health base upon medical history physical examination Willing able participate entire study duration Female subject negative urine pregnancy test immediately prior study vaccination Chronic skin infection chronic skin condition ( e.g . psoriasis ) Serious S. aureus infection last 12 month Allergy aluminumcontaining substance take body vaccine component Oral temperature equal great 100.4ºF ( 38.0ºC ) , within past 2 day Participation prior V710 vaccine clinical study Participation clinical study past 4 week , 3month study duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>study healthy subject</keyword>
</DOC>